Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries

PLoS Medicine

Volumn 8, Issue 2, 2011, Pages

  Mahoney, Richard ^a   Chocarro, Liliana ^b,f   Southern, James ^c   Francis, Donald P ^d   Vose, John ^a   Margolis, Harold ^e  

^a International Vaccine Institute   (South Korea)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c DCVRN   (Switzerland)

^d Global Solutions for Infectious Diseases   (United States)

^e NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^f TORONTO PUBLIC HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

AGE DISTRIBUTION; ARTICLE; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DEVELOPING COUNTRY; DRUG CONTROL; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNIZATION; MORTALITY; NONHUMAN; PREVALENCE; SEROTYPE; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG TOXICITY; GOVERNMENT REGULATION; LEGAL ASPECT; ORGANIZATION; VACCINATION; VIROLOGY;

CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DENGUE; DENGUE VACCINES; DEVELOPING COUNTRIES; DRUG AND NARCOTIC CONTROL; DRUG TOXICITY; GOVERNMENT REGULATION; HUMANS; VACCINATION;

EID: 79952262077     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000418     Document Type: Article

References (21)

1. WHO (2008) Guidelines for the evaluation of dengue vaccines in endemic areas. WHO/IVB/08.12. Available: http://www.who.int/immunization/documents/WHO_IVB_08.12/en/index.html. Accessed 18 January 2011.
2. Edelman R, Hombach J, (2008) Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine 26: 4113-4119.
3. Beatty ME, Letson GW, Margolis HS, (2008) Estimating the global burden of dengue. Second International Conference of Dengue and Dengue Haemorrhagic Fever; 15-17 October 2008; Phuket, Thailand.
4. Herrling P, (2006) Experiments in social responsibility. Nature 439: 267-268.
5. Teixeira Mda G, Costa Mda C, Barreto ML, Mota E, (2005) Dengue and dengue hemorrhagic fever epidemics in Brazil: what research is needed based on trends, surveillance, and control experiences? Cad. Saude Publica de Janeiro, 2005. 21: 1307-1315.
6. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
7. Douglas D, Wichmann O, DeRoeck D, (2009) The perceived need for dengue vaccine in dengue endemic countries. 3rd Vaccine Global Congress; 4-6 October 2009; Singapore.
8. Sabchareon A, Chanthavanich P, Yoksan S, Forrat R, et al. (2004) Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23: 99-109.
9. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, et al. (2002) Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66: 264-272.
10. Siqueira JB Jr, Martelli CM, Coelho GE, Simplicio AC, Hatch DL, (2005) Dengue and dengue hemorrhagic fever, Brazil, 1981-2002. Emerg Infect Dis 11: 48-53.
11. Vanwambeke SO, van Benthem BH, Khantikul N, Burghoorn-Maas C, Panart K, et al. (2006) Multi-level analyses of spatial and temporal determinants for dengue infection. Int J Health Geogr 18: 5.
12. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, et al. (2004) Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop Med Int Health 9: 1022-1029.
13. Batson A, Glass S, Seiguer E, (2003) Economics of vaccines: from vaccine candidate to commercialized product. In: Bloom BR, Lambert PH, editors. The vaccine book London Academic Press pp. 345-370.
14. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
15. Standish K, Kuan G, Avilés W, Balmaseda A, Harris E, (2010) High dengue case capture rate in four years of a cohort study in Nicaragua compared to national surveillance data. Am J Trop Med Hyg 4: e633.
16. Vong S, Khieu V, Glass O, Ly S, Duongg V, et al. (2010) Dengue incidence in urban and rural Cambodia: results from population-based active Fever surveillance, 2006-2008 PLoS Negl Trop Dis 4: e903 doi:10.1371/journal.pntd.0000903.
17. Letson GW, (2009) Dengue surveillance in preparation for field vaccine trials. J Clin Virol 46: S10-S12.
18. Brennan MJ, Fruth U, Milstien J, Tiernan R, de Andrade Nishioka S, et al. (2007) Development of new tuberculosis vaccines: a global perspective on regulatory issues. PLoS Med 4: e252 doi:10.1371/journal.pmed.0040252.
19. Hombach J, (2007) Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev Panam Salud Publica 21: 254-260.
20. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, et al. (2005) Review on flavivirus vaccine development: proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand. Vaccine 23: 2689-2695.
21. WHO (2007) Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses. WHO/IVB/07.07. Available: http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.07_eng.pdf. Accessed 18 January 2011.